<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44276">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529891</url>
  </required_header>
  <id_info>
    <org_study_id>1208090</org_study_id>
    <secondary_id>2012-A01072-41</secondary_id>
    <nct_id>NCT02529891</nct_id>
  </id_info>
  <brief_title>Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>LAVOLEX</acronym>
  <official_title>Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aide à la Recherche Médicale Ondaine et Environs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exacerbations of the disease are a hallmark of Chronic Obstructive Pulmonary Disease (COPD),
      affecting the decline of pulmonary function, quality of life and increasing morbidity. The
      use of validated biomarkers could help to identify the etiology of exacerbation and to
      prescribe antibiotherapy when indicated.

      The analysis of exhaled air allows measuring different volatile organic compounds (VOC)
      which reflect local or systemic inflammation and oxidative stress. The relationship between
      the presence of some of these compounds and the exacerbation of COPD has never been studied.

      The aim of this study is to identify a cluster of VOC in COPD patients during an acute
      exacerbation of the disease, compared to a stable condition (3 months after discharge).
      Investigators also will seek for a relationship between VOC and the etiology of exacerbation
      (bacterial, viral, inflammatory).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Spectrum of VOC measured with a portable mass spectrometer system</measure>
    <time_frame>Day 1 (within 48 hours after hospital admission for exacerbation of COPD)</time_frame>
    <description>Spectrum of VOC in exhaled air in patients with COPD compared to those of control subjects. It is measured with a portable mass spectrometer system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in VOC spectrum in COPD patients measured with a portable mass spectrometer system</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>Variation in VOC spectrum in COPD patients during exacerbation and in stable condition (3 months later). It is measured with a portable mass spectrometer system.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD Patients</arm_group_label>
    <description>Patients with COPD, within 48h after hospital admission for exacerbation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-COPD patients</arm_group_label>
    <description>Healthy person of the entourage of COPD patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of VOC in exhaled air</intervention_name>
    <description>Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer</description>
    <arm_group_label>COPD Patients</arm_group_label>
    <arm_group_label>non-COPD patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with exacerbation of COPD and Healthy volonteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria of COPD group:

          -  COPD stages 2 and 3 of GOLD score (30 ≤ forced expiratory volume at one second (FEV1)
             &lt; 80% of predicted value),

          -  exacerbation confirmed clinically (increased dyspnea, cough or expectorations &gt; 48
             hours)

        Inclusion Criteria of non COPD group:

          -  No smoker (&lt;100 cigarettes/year)

        Exclusion Criteria of COPD group:

          -  Diagnosis of COPD not confirmed.

          -  Instable clinical status with respiratory failure and indication of mechanical
             ventilation.

          -  Bronchodilator treatment changed

          -  Antibiotic treatment started in the 10 last days before admission

        Exclusion Criteria of non COPD group:

          -  Chronic inflammatory disease

          -  Any respiratory disease

          -  Oral corticosteroid treatment during the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic COSTES, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic COSTES, MD PhD</last_name>
    <phone>(0)477828695</phone>
    <phone_ext>+33</phone_ext>
    <email>frederic.costes@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>arnauld.garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Michel VERGNON, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle COURT-FORTUNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry BASSET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric COSTES, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Claude BARTHELEMY, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie CHAUMETTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime SAUVAGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>August 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Volatile Organic Compounds</keyword>
  <keyword>Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
